A Study to Evaluate Adverse Events and Change in Disease Activity of Mirvetuximab Soravtansine-gynx in Adults With Folate Receptor-Alpha Positive, Platinum-Resistant Ovarian Cancer in a Real-World Setting
← catalyst calendarNCT07687602 · readout ≤ 1,838 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
—
Status
Not yet recruiting
Study type
Observational
Enrollment
69estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-06-30 | estimated | When the study began enrolling |
| Primary completion | Aug 2031 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2031 | estimated | The whole study's end, after follow-up |
| First posted | 2026-07-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Folate Receptor-Alpha Positive Platinum-Resistant High-Grade Serous Epithelial Ovarian Cancer
- Folate Receptor-Alpha Positive Platinum-Resistant Fallopian Tube Cancer
- Folate Receptor-Alpha Positive Platinum-Resistant Primary Peritoneal Cancer
Primary outcome
what the primary-completion date above is the date OFNumber of Participants With Adverse Events (AE)s
measured Up to Approximately Up to 62 Months
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed